The $90B Leakage Problem:
What Pharma Must Know About Gross-to-Net (GTN) Risk
About this webinar
Pharmaceutical manufacturers are facing a significant systemic failure: an estimated $90 billion in annual revenue leakage driven by copay programs, accumulators, maximizers and other misaligned industry dynamics. This leakage not only erodes Gross-to-Net (GTN) performance but also disrupts patient access and continuity of care.
This webinar examines the structural drivers behind GTN leakage and outlines practical strategies to address risk earlier in the patient access journey.
Drawing on frontline pharmacy and access workflow experience, this webinar explores how GTN leakage begins during program enrollment, and why retrospective audit approaches often fail to protect either revenue or patients. The discussion highlights how real-time intervention at enrollment can identify benefit design misalignment sooner, reduce avoidable leakage and improve access reliability.
Attendees will gain a practical understanding of:
- The primary structural drivers of GTN revenue leakage including accumulators, maximizers, alternative funding programs and pharmacy-level copay dynamics
- How GTN leakage directly impacts patient access, continuity of care and overall patient experience
- Why retrospective audits after enrollment fail to adequately mitigate financial exposure or access disruption
- How real-time intervention at enrollment can reduce GTN leakage while improving revenue predictability and access outcomes
With GTN performance now a board-level priority and profitability under increasing pressure, reactive strategies are no longer sufficient.
Join this webinar to learn how pharmaceutical manufacturers can protect GTN while improving patient access.
Who should attend
- Directors and Senior Managers, Market Access and Managed Markets
- Directors, Patient Access and Patient Support Programs
- Directors, Pricing, Contracting and Reimbursement
- Senior Managers and Payer Strategy
- Directors, Commercial Operations and Commercial Excellence
- Product Management and Commercial Strategy Managers
- Business Development and Partnership Leaders (Access & HEOR)
What you will learn
- What is causing GTN revenue leakage, and where does the $90B in lost revenue goes including accumulators, maximizers, AFPs and pharmacy copay misuse
- How GTN leakage undermines the patient experience and why access models fail at the pharmacy counter
- Why retroactive audits after enrollment can’t protect patients or revenue and how real-time GTN intervention at enrollment can prevent leakage from happening
- How manufacturers can translate affordability spend into measurable access outcomes and revenue performance
Featured Speakers
Gerard Rivera
Gerard serves as CEO of RIS Rx, which he co-founded in 2020. In partnership with the RIS Rx Executive team, Gerard is pioneering GTN revenue protection with direct impact on millions of patients and the pharmaceutical manufacturers that support them. His background spans frontline pharmacy, patient access & affordability operations, with leadership experience across multiple pharmacy services and healthcare organizations. He earned his PharmD from Loma Linda University.
Stephen Hom
Stephen Hom, PharmD, serves as Chief Operating Officer of RIS Rx, which he co-founded in 2020. Stephen manages all aspects of operations in RIS Rx’s patient affordability, benefit design and GTN revenue protection solutions for pharma manufacturers, routinely combining his deep knowledge as a Frontline Pharmacist with scalable tech-enabled workflows to support the lives of millions of patients. He earned his PharmD from Loma Linda University.
Partner for this event
RIS Rx
Every patient. Every dollar. Protected.
RIS Rx is a healthcare technology company delivering gross-to-net (GTN) revenue protection for the world’s leading pharmaceutical manufacturers. Through proprietary software, real-time analytics and pharmacist-led expertise, RIS Rx helps clients optimize operations, eliminate leakage and ensure that financial assistance reaches the patients who need it most. In 2025 alone, the company protected more than $1 billion in revenue for its customers. Founded in 2020 and headquartered in Irvine, California, RIS Rx serves leading pharmaceutical manufacturers across a growing portfolio of drug brands. Learn more at www.RISRx.com.
